P
Peng Li
Researcher at Bristol-Myers Squibb
Publications - 27
Citations - 354
Peng Li is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Supercritical fluid chromatography & Bruton's tyrosine kinase. The author has an hindex of 8, co-authored 25 publications receiving 236 citations.
Papers
More filters
Journal ArticleDOI
Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers.
Scott H. Watterson,George V. De Lucca,Qing Shi,Charles M. Langevine,Qingjie Liu,Douglas G. Batt,Myra Beaudoin Bertrand,Hua Gong,Jun Dai,Shiuhang Yip,Peng Li,Dawn Sun,Dauh-Rurng Wu,Chunlei Wang,Yingru Zhang,Sarah C. Traeger,Mark A. Pattoli,Stacey Skala,Lihong Cheng,Mary T. Obermeier,Rodney Vickery,Lorell Discenza,Celia D’Arienzo,Yifan Zhang,Elizabeth M. Heimrich,Kathleen M. Gillooly,Tracy L. Taylor,Claudine Pulicicchio,Kim W. McIntyre,Michael Galella,Andy J. Tebben,Jodi K. Muckelbauer,Chiehying Chang,Richard Rampulla,Arvind Mathur,Luisa Salter-Cid,Joel C. Barrish,Percy H. Carter,Aberra Fura,James R. Burke,Joseph A. Tino +40 more
TL;DR: The structure-activity relationships (SAR) leading to a novel series of highly potent and selective carbazole and tetrahydrocarbazole based, reversible inhibitors of BTK are detailed, resulting in enhanced potency and selectivity as well as a reduction in safety liabilities.
Journal ArticleDOI
Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors.
Chunjian Liu,James Lin,Moslin Ryan M,John S. Tokarski,Jodi K. Muckelbauer,Chiehying Chang,Jeffrey Tredup,Dianlin Xie,Hyunsoo Park,Peng Li,Dauh-Rurng Wu,Joann Strnad,Adriana Zupa-Fernandez,Lihong Cheng,Charu Chaudhry,Jing Chen,Cliff Chen,Huadong Sun,Paul A. Elzinga,Celia D’Arienzo,Kathleen M. Gillooly,Tracy L. Taylor,Kim W. McIntyre,Luisa Salter-Cid,Louis J. Lombardo,Percy H. Carter,Nelly Aranibar,James R. Burke,David S. Weinstein +28 more
TL;DR: In sharp contrast to a previously reported series of 6-anilino imidazopyridazine based Tyk2 JH2 ligands, 6-((2-oxo-N1-substituted-1,2-dihydropyridin-3-yl)amino)imidazo[1-2-b]pyridazines analogs were found to display dramatically improved metabolic stability.
Journal ArticleDOI
Rationally Designed, Conformationally Constrained Inverse Agonists of RORγt—Identification of a Potent, Selective Series with Biologic-Like in Vivo Efficacy
David Marcoux,Jingwu Duan,Qing Shi,Robert J. Cherney,Anurag S. Srivastava,Cornelius Lyndon A M,Douglas G. Batt,Qingjie Liu,Myra Beaudoin-Bertrand,Carolyn A. Weigelt,Purnima Khandelwal,Sureshbabu Vishwakrishnan,Kumaravel Selvakumar,Ananta Karmakar,Arun Kumar Gupta,Mushkin Basha,Sridharan Ramlingam,Naveen Manjunath,Sridhar Vanteru,Sukhen Karmakar,Nageswara Maddala,Muthalagu Vetrichelvan,Anuradha Gupta,Richard Rampulla,Arvind Mathur,Shiuhang Yip,Peng Li,Dauh-Rurng Wu,Javed Khan,Max Ruzanov,John S. Sack,Jinhong Wang,Melissa Yarde,Mary Ellen Cvijic,Sha Li,David J. Shuster,Virna Borowski,Jenny Xie,Kim W. McIntyre,Mary T. Obermeier,Aberra Fura,Kevin Stefanski,Georgia Cornelius,John Hynes,Joseph A. Tino,John E. Macor,Luisa Salter-Cid,Rex Denton,Qihong Zhao,Percy H. Carter,T. G. Murali Dhar +50 more
TL;DR: In this paper, a series of tricyclic RORγt inverse agonists with significantly improved in vitro activity in the reporter (Gal4) and human whole blood assays compared to our previous chemotype were identified.
Journal ArticleDOI
Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms.
Honghe Wan,Gretchen M. Schroeder,Hart Amy C,Jennifer Inghrim,Grebinski James W,John S. Tokarski,Matthew V. Lorenzi,Dan You,Theresa M. McDevitt,Becky Penhallow,Ragini Vuppugalla,Yaqun Zhang,Xiaomei Gu,R Iyer,Louis J. Lombardo,George L. Trainor,Stefan Ruepp,Jonathan Lippy,Yuval Blat,John S. Sack,Javed Khan,Kevin Stefanski,Bogdan Sleczka,Arvind Mathur,Jin-Hua Sun,M.K Wong,Dauh-Rurng Wu,Peng Li,Ashok Kumar Gupta,Pirama Nayagam Arunachalam,Bala Pragalathan,S Narayanan,Prakasam Kuppusamy,Ashok V. Purandare +33 more
TL;DR: A clinical candidate with excellent kinome selectivity, in vivo PD activity, and safety profile is discovered, BMS-911543, for the treatment of myeloproliferative neoplasms possessing a deregulated JAK2-STAT pathway.
Journal ArticleDOI
From analytical methods to large scale chiral supercritical fluid chromatography using chlorinated chiral stationary phases.
TL;DR: The challenges associated with several SFC applications on both coated and immobilized chlorinated CSP to deliver high-quality drug candidates in large quantity are discussed and the use of dichloromethane in both sample preparation and as co-solvent in CO2 to increase sample solubility is presented.